Digest Network Come funziona
Network
/
Società
Hi
Non verificato

HighField Biopharmaceuticals

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

5 comunicati stampa

Guarda tutti i comunicati
21/04/2025
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
HighField Biopharmaceuticals Files INDs for Two ADCplex™ Immunoliposomes with Different Cancer Killing Payloads to Overcome Limitations of Current ADCs
Fonte
HighField Biopharmaceuticals
Emittente
Business Wire
1.00
0
13/01/2025
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Studies by HighField Biopharmaceuticals Show Advantages of Lipid Structure Design for Applying LNP Non-Viral Gene Therapies to Complex Diseases
Fonte
HighField Biopharmaceuticals
Emittente
Business Wire
1.00
0
17/12/2024
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
HighField Biopharmaceuticals Granted Clearance of IND in China for Clinical Trial of its Unique TRAFsomeTM T Cell Engager (HF50) To Treat Solid Tumor Cancers
Fonte
HighField Biopharmaceuticals
Emittente
Business Wire
1.00
0
16/09/2024
Analisi di mercato
Industria
Oncologia
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers
Fonte
HighField Biopharmaceuticals
Emittente
Business Wire
1.00
0
03/09/2024
Oncologia
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
HighField Biopharmaceuticals Files IND in China for Clinical Trial of HF50, a Unique Lipid-Based T Cell Engager, to Treat Solid Tumor Cancers
Fonte
HighField Biopharmaceuticals
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0